wouldn t this be nice

Deals seem to happen in Europe - hopefully, the remoteness of Australia won't prevent a deal for ACL ...

Novartis plans to buy its research partner, Swiss biotech company Speedel, for about $880 million to speed up development of potential blockbuster blood-pressure drug Tekturna, it said on Thursday.

Speedel shares surged more than 90 percent to the offer price after the latest in a string of big pharma acquisitions of promising start-up drug development companies.

Cash-rich major drugmakers have been queuing up to invest in medicines to fill their thinning pipelines -- and the biotech sector has been hit by the global downturn in equity markets, fuelling takeover speculation.